Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Mar 18;41(3):227–237. doi: 10.1111/1440-1681.12204

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Clinical and Experimental Pharmacology and Physiology Published by Wiley Publishing Asia Pty Ltd.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Fig. 6 — (a) Left ventricular weight (LVW) : tibia length ratio (mg/mm), (b) glomerulosclerosis index (GSI) and (c) glomerular volume in the late phase (i.e. 20 weeks after 5/6 renal mass reduction (5/6 NX)) in sham-operated Hannover Sprague-Dawley rats (HanSD; transgene negative; ) and heterozygous Ren-2 transgenic rats (TGR; ▪), as well as in TGR rats after 5/6 renal mass reduction (5/6 NX) that were either untreated () or treated with: (i) combined renin–angiotensin system (RAS) blockade with trandolapril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin receptor blocker (); or (ii) the soluble epoxide hydrolase inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (). Data are the mean ± SEM. *P < 0.05 compared with sham-operated HanSD rats; ^†P < 0.05 compared with sham-operated TGR. (), HanSD; (), 5/6 NX TGR + water; (), 5/6 NX TGR + sEHi; (▪), TGR; (), 5/6 NX TGR + RAS blockade.

Inline graphic — (a) Left ventricular weight (LVW) : tibia length ratio (mg/mm), (b) glomerulosclerosis index (GSI) and (c) glomerular volume in the late phase (i.e. 20 weeks after 5/6 renal mass reduction (5/6 NX)) in sham-operated Hannover Sprague-Dawley rats (HanSD; transgene negative; ) and heterozygous Ren-2 transgenic rats (TGR; ▪), as well as in TGR rats after 5/6 renal mass reduction (5/6 NX) that were either untreated () or treated with: (i) combined renin–angiotensin system (RAS) blockade with trandolapril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin receptor blocker (); or (ii) the soluble epoxide hydrolase inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]benzoic acid (). Data are the mean ± SEM. *P < 0.05 compared with sham-operated HanSD rats; ^†P < 0.05 compared with sham-operated TGR. (), HanSD; (), 5/6 NX TGR + water; (), 5/6 NX TGR + sEHi; (▪), TGR; (), 5/6 NX TGR + RAS blockade.